A Randomized Comparison of Intensive Maintenance Treatment for Adult Acute Myelogenous Leukemia Using Either Cyclic Alternating Drugs or Repeated Courses of the Induction-Type Chemotherapy: AML-6 Trial of the EORTC Leukemia Cooperative Group
Standard induction treatment of patients with de novo acute myelogenous leukemia (AML) results in a complete remission (CR) rate of 60%–80%. However, remission duration is usually short with a relapse rate of about 70% within the first 2 years independent of various consolidation and maintenance modalities. The rate of long-term remitters at 4 – 5 years is no higher than 20%–30%. The role of maintenance treatment is controversial. Generally, repeated short courses of intravenous or subcutaneous cytarabine with thioguanine or daunorubicin are given monthly for 2–3 years. Numerous controlled and uncontrolled trials with few exceptions have failed to demonstrate a substantial benefit in patients receiving maintenance therapy compared with those receiving induction and consolidation alone [1–11]. Two other studies [12, 13] reported superior results with maintenance therapy, but this was probably due to unexpectedly poor results among controls .
KeywordsAcute Myeloid Leukemia Complete Remission Acute Myelogenous Leukemia Cytosine Arabinoside Remission Maintenance
Unable to display preview. Download preview PDF.
- 1.Champlin R, Jacobs A, Gale RP et al. (1984) Prolonged survival in acute myelogenous leukemia without maintenance chemotherapy.Google Scholar
- Lancet 1:894Google Scholar
- 4.Embury SH, Elias L, Heller DH et al. (1979) Remission maintenance therapy in acute myelogenous leukemia. West J Med 126: 267Google Scholar
- 5.Rees JKG, Hayhoe FGJ (1984) Treatment of acute myeloid leukemia following remission. Results of a large cooperative study in the UK. Proc Am Soc Clin Oncol 3: 190 (abstract)Google Scholar
- 9.Toronto Leukemia Study Group (1988) Survival in acute myeloblasts leukemia is not prolonged by remission maintenance or early re-induction chemotherapy. Leuk Res 12: 195Google Scholar
- 10.Hayat M, Jehn U, Willemze R et al. (1986) A randomized comparison of maintenanceGoogle Scholar
- 283.treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the E.O.R.T.C. Cancer 58: 617Google Scholar
- 12.Biichner T, Urbanitz D, Hiddemann W et al. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia. J Clin Oncol 3: 1583Google Scholar
- 14.Champlin R, Gale GP (1987) Acute myelogenous leukemia: recent advances in therapy. Blood 69:1551 15. Dutcher JP, Wiernik PH, Markus S et al. (1988) Intensive maintenance therapy improves survival in adult acute non-lymphocytic leukemia: an eight year follow-up. Leukemia 2: 413Google Scholar
- 16.Champlin RE, Ho WG, Gale RP (1985) Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med 102: 285Google Scholar